



*Search for Chief, Division of Breast Medical Oncology  
Fox Chase Cancer Center  
Philadelphia, Pennsylvania*

## **THE SEARCH**

The Fox Chase Cancer Center (Fox Chase or FCCC) invites applications and nominations to fill the position of Chief, Division of Breast Medical Oncology in the Department of Hematology/Oncology. This is an outstanding opportunity for an emerging leader in the field of breast medical oncology to further develop and implement a strategic vision for the division's clinical and research activity. As one of the original National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation, Fox Chase has a celebrated history of scientific discovery and compassionate care. The new division chief will step into the role at an exciting time as Fox Chase's affiliation with Temple University Health System (TUHS) enters an exciting and reinvigorated stage.

The Chief will lead a division of nine full-time faculty members and three advanced practice providers. Sitting within the Department of Hematology/Oncology, the division has numerous collaborations in place across Fox Chase, most notably with Surgical Oncology, Radiation Oncology, Plastic and Reconstructive Surgery, Imaging, Prevention, and Genetic Assessment. Drawing on the strength of these collaborations and the FCCC's emerging research prominence, the new Division Chief will be expected to develop and implement a strategic vision for continued high-quality clinical care and emerging research prominence.

The ideal candidate will have earned an MD or MD/PhD degree, hold a subspecialty board certification in Medical Oncology, and have a proven track record with leadership experience in an academic or cancer center setting. Bringing a portfolio of extramural support (industry and/or peer-reviewed) in research with a specific focus on innovative therapeutics clinical trials, the successful candidate will qualify for the rank of Associate or Full Professor and will be actively involved in National Clinical Trials Network initiatives, such as ECOG-ACRIN and NRG. Applying strong leadership and communication skills in clinical care, teaching, and mentoring, the next Chief will exemplify a commitment to excellence and champion a diverse, equitable, and inclusive environment.

With the resources and support from the Department of Hematology/Oncology and other Fox Chase leaders, the new Chief will be well situated to deliver on stated goals: elevating and further developing the division's research portfolio; recruiting, mentoring, and retaining outstanding faculty; managing efficient clinical operations; and nurturing and effectuating existing and new collaborative relationships across the enterprise.



*Fox Chase Cancer Center has retained the search firm Isaacson, Miller to assist with this important recruitment. Instructions for applying, nominating, and inquiring about the position can be found towards the end of this document.*

## FOX CHASE CANCER CENTER

Fox Chase Cancer Center was established in 1974 through the merger of the American Oncologic Hospital, founded in 1904 as one of the country's first cancer-focused hospitals, and the Institute for Cancer Research, founded in 1927. That same year, Fox Chase was one of the first centers to earn the comprehensive designation from the National Cancer Institute (NCI), a distinction it has held for the last 55 years. As a founding member of the National Comprehensive Cancer Network and a dedicated cancer center, Fox Chase's mission is "to prevail over cancer, marshaling heart and mind in bold scientific discovery, pioneering prevention, and compassionate care." Fox Chase's catchment area comprises six counties in southeastern Pennsylvania and nine counties in southern New Jersey, encompassing nearly 7.3 million people.

Over the course of its history, the FCCC has offered nationally competitive basic, translational, and clinical research, as well as special programs in cancer prevention, detection, survivorship, and community outreach. Efforts at Fox Chase have led to multiple ground-breaking discoveries, including research that identified the "Philadelphia Chromosome" and led to the development of the field of cancer genetics, as well as the discovery of the hepatitis B virus and the development of a vaccine against it. This resulted in one of the two Nobel Prizes being awarded to Fox Chase faculty.

Fox Chase is home to 159 current members – 116 primary and 43 collaborating – focused on four main research programs:

- Cancer Signaling and Epigenetics
- Blood Cell Development and Function
- Molecular Therapeutics
- Cancer Prevention and Control

In 2021, Fox Chase had 479 active research projects with just under \$72 million in total funding. With a particular emphasis on clinical research, physician-scientists conducted 121 phase 1-3 intervention/treatment studies; over 100 non-interventional ongoing studies; and 91 investigator-initiated clinical research studies. Fox Chase researchers participate in consortia related to population health, including the Breast Cancer Family Registry and the Cancer Health Disparities Geographic Management Program.

**Shared resources** at Fox Chase provide members access to services and specialized technologies, including the following:

- Biological Imaging Facility
- Biosample Repository Facility
- Biostatistics and Bioinformatics Facility
- Cell Culture Facility
- Cell Sorting Facility
- Genomics Facility
- High Throughput Screening Facility
- Histopathology Facility
- Laboratory Animal Facility
- Molecular Modeling Facility
- Population Studies Facility
- Transgenic Mouse Facility

With a long-standing commitment to providing the best in compassionate care, Fox Chase registered 140,503 outpatient visits and 8,631 new patients in 2021 with 17% of the total patient population being breast cancer patients. Clinical services are offered at the main campus in Northeast Philadelphia as well as five additional facilities in Philadelphia and Bucks County, including Temple University Hospital in North Philadelphia and the TUHS-Northeastern site.

Fox Chase Cancer Center has a strong and growing philanthropic enterprise. In 2021, Fox Chase once again exceeded its annual fundraising goal by raising nearly \$17 million, enabling new and expanded programs and services, and more cancer research.

### ***Temple University Health System***

Fox Chase's affiliation with Temple University (TU) and Temple University Health System (TUHS) began in 2012. Through this arrangement, Fox Chase combines the flexibility of a free-standing cancer center with the scientific and clinical power of a large academic health system. Over the past decade, the size and scope of Fox Chase have expanded in terms of its scientific portfolio, the number of patients served, and the diversity of its patient population to include those from the underserved communities surrounding Temple University Health Science Center in North Philadelphia. In addition, a number of cancer-focused Temple faculty have been integrated into Fox Chase, including several in leadership positions. The affiliation not only expands the Fox Chase membership base, but also enables access to the specialized expertise at Temple University, including the Moulder Center for Drug Discovery and the School of Public Health.

And although Fox Chase was at the center of highly publicized acquisition conversations between Temple University and Thomas Jefferson University which did not come to fruition, TUHS CEO Michael Young has renewed the investment in Fox Chase Cancer Center, pledging support in the amount of \$100 million over five years. The health system has also provided new state-of-the-art surgical, imaging, and basic research tools, with future investments slated to occur in faculty recruitment and in clinical and research infrastructure. Fox Chase continues to be a major revenue-generator for TUHS.



### ***The Division of Breast Medical Oncology***

Currently led by Interim Chief Elias Obeid, MD, MPH, the Division of Breast Medical Oncology takes a multidisciplinary approach to the treatment and diagnosis of breast cancer. The Division's nine medical oncologists collaborate in tandem with clinicians in Surgery (5), Breast Imaging (2), Prevention and Genetic Assessment (3), Plastic and Reconstructive Surgery (1), and Radiation Oncology (4), as well as three Advanced Practice Clinicians. Together they provide a full spectrum of care for every type and stage of breast cancer, from detection through survivorship.

The Fox Chase Office of Clinical Research has \$12 million of active grants inclusive of NIH, NCI, and other contracted projects. Clinically, Fox Chase has overaged 6,900 annual medical oncology visits over the past five years, with approximately 2% annual growth. On average, there are 3,185 surgery clinic visits per year with 5-7% year-over-year growth, and 585 surgeries per year with 2-3% year-over-year increase.

Sitting alongside the Division, the Breast Cancer Program, led by Dr. Richard Bleicher, provides state-of-the-art care and expertise in open, endoscopic, laparoscopic, and robotic surgery. The team is involved in a wide variety of clinical trials for emerging and innovative therapies for breast cancer.



## THE ROLE OF THE DIVISION CHIEF

The Chief of the Division of Breast Medical Oncology reports to Dr. Martin Edelman, Chair of the Department of Hematology/Oncology. Slated with overseeing the division's education programs, research portfolio, and all clinical activities, the Chief will have a package that supports the recruitment of new and the retention of existing faculty, and as such, will manage the Division's financial resources. Chiefs at Fox Chase are given considerable autonomy to advance an overarching strategy for their respective divisions.

## OPPORTUNITIES AND CHALLENGES

The next Chief of the Division of Breast Medical Oncology will have the opportunity to assess and address the following opportunities for impact and the challenges to achieving that impact:

### *Develop a strategic vision for the division*

Working in close collaboration with the Chair of Hematology/Oncology, the Chief will develop a strategic vision for the division with the aim of strengthening its academic programs, increasing, and elevating its basic and clinical research, and effectively addressing an increase in clinical volumes to ensure excellent care across the division.

### *Ensure effective, efficient, and patient-centered clinical operations*

The Chief will ensure that the Division's clinical operations are optimally structured to effectively support a robust (and growing) volume of clinical activity. To do so, the Chief will work in tandem with Dr. Richard Bleicher to continuously assess and fine-tune the division's organizational structure, adjusting staffing levels and patterns; hours of operation; and physical space, including size, design, and capacity as needed. At all times, the Chief will lead and enable the Division to provide the highest quality of care, timely access, and support to meet the needs of patients and families while also ensuring physicians are positioned to provide optimal care.

### *Increase and enhance research, especially therapeutics-related clinical trials*

By driving a multi-disciplinary research strategy of the highest quality, the Chief will help fuel the translation of new discoveries and improvements in human health. To achieve this aim, the Chief will lead the Division in growing its research enterprise, based on existing strengths and emerging opportunities, especially in clinical trials that support therapeutics. The Chief will support and inspire faculty members at all levels, and, in leading by example, will engage and advise faculty on securing and sustaining funding, and on collaborations that increase scholarly publications. The Chief will also work to build intra- and inter-institutional collaboration to advance research projects and initiatives.

***Recruit, retain, and mentor faculty***

To support the current and anticipated growth of the Division, the Chief will apply a well-honed eye for identifying and recruiting top talent. Of equal importance will be nurturing and developing the existing faculty. The Chief will identify and implement real pathways for growth and build structures for formal mentoring. Applying a leadership model based on a generosity of spirit, the Chief will galvanize and inspire continued success across all missions, serving as a champion for faculty, staff, and fellows and connecting their work to the broader FCCC missions.

***Advocate for the division and build partnerships within the Cancer Center and across TUHS***

The Chief will serve as an ambassador for the division, raising its profile and engaging with a vibrant and influential community of practitioners at Fox Chase and across the TUHS landscape. By building multi-disciplinary partnerships between cancer center members and other practitioners, the Chief will ensure the Division provides an excellent patient experience while also advancing science related to breast cancer. In the context of the reinvigorated affiliation with TUHS, the Chief will identify ways for division members to plug into new and existing opportunities across the Temple community, especially in the areas of health equity and access.

***Strengthen diversity, equity, and inclusion within the Division***

It is paramount that the Chief continues the ongoing efforts to diversify the faculty, staff, and fellows and be equally vigilant in ensuring the strongest possible commitment to inclusion and equity. The Division values diversity and inclusion as essential to each of its core missions (clinical care, research, and education). The Chief must foster an environment in which all are valued, are heard, and have the ability to reach their individual and collective potential. The Chief is responsible for creating community wherever possible; leading culture change; changing structures and policies where necessary; and ensuring transparency about critical decisions.

**DESIRED QUALIFICATIONS AND EXPERIENCES**

The ideal candidate will bring the following skills, qualities, and experience which are considered critical to success:

- An MD or MD/PhD with a record of achievement suitable for appointment at the level of Associate or Full Professor.
- Board certification in medical oncology
- Experience and knowledge of clinical trials, including Investigator-Initiated Trials, NCI-NCTN trials, and industry-sponsored trials.
- Successful track record in scholarly achievement and success in obtaining extramural funding, particularly in therapeutics.
- History of participation in NCI-sponsored national clinical research groups such as ECOG-ACRIN and NRG.
- Progressive administrative and operational experience, preferably in an academic medical center or cancer center setting.

- A track record of partnering with a breadth of stakeholders to develop, inspire, communicate, and operationalize a shared vision and strategic plan.
- Commitment to diversity and inclusion as lived values and evidence of building cultures that ensure equity.
- Strong ability to collaborate and build trust with a diverse group of stakeholders within large and complex organizations.
- Success leading or supporting faculty recruitment, retention, and development efforts that enhance academic excellence, diversity, equity, and inclusion.
- Strong acumen and judgment in managing financial resources and the ability to develop and implement budgets effectively, aligning resources with strategic priorities.



### APPLYING, NOMINATING, AND INQUIRING

Interested applicants are invited to submit their current CV/resume and statement of interest to:

Patricia Hastie & Caitlin Barrett  
Isaacson, Miller

Review of applications will begin immediately and continue until the position is filled.  
Electronic submissions of applications or nominations are strongly preferred and can be made at [www.imsearch.com/8362](http://www.imsearch.com/8362).

***Fox Chase Cancer Center is an Equal Opportunity/Affirmative Action Employer. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.***

**ADDENDUM*****Leadership*****Dr. Martin Edelman, MD****Chair, Department of Hematology/Oncology****Deputy Cancer Center Director for Clinical Research**

A nationally recognized expert in the treatment and research of lung cancer, Dr. Edelman collaborates with the FCCC clinical, scientific, and administrative leadership to grow robust therapeutic, clinical research, and translational research programs in hematology and medical oncology. He is a graduate of the combined BS-MD program of Rensselaer Polytechnic Institute and the Albany Medical College. He was a resident in Internal Medicine and Fellow in Hematology/Oncology at the U.S. Naval Medical Center in San Diego. Prior to joining Fox Chase in 2017, Dr. Edelman was on the faculty of the University of California, Davis and the University of Maryland. He is a “Top Doc” for Castle Connolly and Philadelphia Magazine.

Dr. Edelman serves on the Thoracic Malignancies Steering Committee of the National Cancer Institute’s Scientific Review Group. In addition, he is the Medical Oncology Co-chair for the Lung Cancer Committee of the Radiation Therapy Oncology Group (RTOG), a member of the ECOG lung committee, and is an active member and past chair of the Career Development and Ethics Committees of the International Association for the Study of Lung Cancer (IASLC). He has been the national PI for trials in SWOG, Alliance, and NRG.

Dr. Edelman has published more than 400 scientific articles, abstracts, and book chapters. In addition, he has served on the editorial boards or as an ad-hoc reviewer of numerous academic journals, including the Journal of Clinical Oncology, the Journal of Thoracic Oncology, and currently serves as Associate Editor of the journal Lung Cancer.

**Dr. Robert Uzzo, MD, MBA, FACS****Interim CEO, Hospital of Fox Chase Cancer Center****Chair, Department of Surgery**

Nationally known as a leader in the field of urologic oncology, Dr. Uzzo has made important clinical, scientific, and educational contributions to the Department of Surgery.

A fellow of the American College of Surgeons, Uzzo has consistently ranked among Castle Connolly’s and Philadelphia Magazine’s “Top Docs” in urology. He is a national principal investigator for a clinical trial by the Eastern Cooperative Oncology Group to evaluate new, targeted therapies for kidney cancers and immunotherapy. He is the author of more than 350 chapters, articles, books, and abstracts on urologic tumors and has presented hundreds of regional, national and international lectures.

Before joining the Fox Chase team in 2000, Dr. Uzzo was a fellow and clinical staff member at the Cleveland Clinic Foundation. He received his MD at Cornell University Medical College, followed by his internship and residency in surgery at the New York Hospital - Cornell University



Medical Center. Dr. Uzzo continued his residency in urology there and at Memorial Sloan-Kettering Cancer Center, serving as chief resident in New York Hospital's department of urology.

**Dr. Jonathan Chernoff, MD, PhD**  
**Fox Chase Cancer Center Director**

Dr. Chernoff leads the Fox Chase Cancer Center as its Director. He is a long-time member of the Fox Chase community, having joined the staff in 1991 as an associate member before being promoted to member with tenure in 1996. In 2002 he was promoted to be a senior member in Fox Chase Cancer Center's Basic Science division, the equivalent of a full professor in a university.

A molecular oncologist as well as a board-certified medical oncologist, Dr. Chernoff has a special interest in factors that control cell growth and movement, including oncogenes and anticancer or tumor-suppressor genes, and has made fundamental contributions in this research.

Chernoff earned his MD and his PhD in biochemistry in 1984 at Mount Sinai School of Medicine in New York City. He completed his residency in internal medicine at the University Health Center of Pittsburgh and a clinical fellowship in medical oncology at Johns Hopkins Oncology Center. He then held a postdoctoral fellowship in cellular and developmental biology at Harvard University before coming to Fox Chase.

To learn more about FCCC leadership, please visit: <https://www.foxchase.org/about-us/administrative-leaders>

**Michael Young**  
**Chief Executive Officer, Temple University Health System (TUHS) and President and CEO, Temple University Hospital (TUH)**

Michael Young joined Temple as Chief Operating Officer of TUH in 2018 and was appointed CEO of the hospital in 2019 and CEO of TUHS in 2020. He is a seasoned health care CEO with more than 30 years of leadership experience at large academic medical centers including the Pinnacle Health System in Harrisburg; Grady Memorial Hospital in Atlanta; Erie County Medical Center in Buffalo; and Lancaster General Hospital & Health System. He holds Board certification in healthcare management as a Fellow of the American College of Healthcare Executives (FACHE), and he holds a master's degree in Health Administration, as well as a bachelor's degree in Biology from the University of Pittsburgh.

To learn about TUHS leadership, please visit: <https://www.templehealth.org/about/leadership>